Moderna is counting on its product pipeline to resuscitate its ailing stock
Moderna Inc.’s stock fell 3% early Friday, after the biotech posted a wider-than-expected fourth-quarter loss and offered soft guidance for 2025, offsetting a revenue beat. Cambridge, Mass.-based ...